IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability - IGC Pharma, INC.

Press

Releases

September 8, 2021

IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

Related Posts

IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market

May 22, 2025

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025

IGC Pharma Welcomes Strategic Investment from Advisors

April 24, 2025

CEO Update

igc pharma

IGC Pharma Inc 8K – Clinical Study Update Jun 17’25

June 17, 2025

IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market

May 22, 2025